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Abstract
Objective: Lentivirus-derived vectors are among the most promising viral vectors for 
gene therapy which is currently available, but their use in clinical practice is limited 
due to associated risk of insertional mutagenesis. Gene targeting is an ideal method 
for gene therapy, but it has low efficiency in comparison to viral vector methods. In 
this study, we are going to design and construct an integrase-minus lentiviral vector. 
This vector is suitable for transient expression of gene and gene targeting with viral 
vector. 
Materials and Methods: In this experimental study, three missense mutations were 
induced in the catalytic domain of Integrase gene in the pLP1 plasmid and resulted 
D64V, D116A and E152G changes in the amino acid sequence through site directed 
mutagenesis. The pLenti6.2-GW/EmGFP transfer vector, associated with native and 
mutated packaging mix, was transfected into 293T cell line. In order to titer the len-
tivirus stock, the viruses were harvested. Finally, the viruses transduced into COS-7 
cell line to assess green fluorescent protein (GFP) gene expression by a fluorescence 
microscopy.
Results: Recombinant and wild lentiviruses titer was about 5~8×106 transducing units/
ml in COS-7 cell line. The number of GFP-positive cells transduced with native viruses 
was decreased slightly during two weeks after viral transduction. In contrast, in the case 
of integrase-minus viruses, a dramatic decrease in the number of GFP positive cells was 
observed. 
Conclusion: This study was conducted to overcome the integration of lentiviral ge-
nome into a host genome. Nonintegrating lentiviral vectors can be used for transient 
gene expression and gene targeting if a Target gene cassette is placed in the len-
tivirus gene structure. This combination method decreases disadvantages of both 
processes, such as random integration of lentiviruses and low efficiency of gene 
targeting.
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Introduction
Vectors based on retroviruses and lentiviruses 
have been used to introduce genes efficiently and 
stably into cells for long-term expression. Their 
ability to stable transduces in cells is due to en-
code integrase protein in their genomes. This pro-
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tein identifies specific sequences called long 
terminal repeats (LTR) in the virus genome and 
led to the insertion of these sequences in the 
host chromosomes (1, 2). Lentiviral vectors 
can deliver up to 8 kb of DNA of interest. They 
can be pseudotyped, so they display the chosen 
tropism. In addition, the lentiviral vectors can 
transduce dividing cells and non-dividing cells 
(3, 4), a great advantage for genetically modify-
ing tissues, such as brain, muscle, liver, lungs, 
and hematopoietic system. They are easily pro-
duced without need of helper particles, and they 
are only weakly immunogenic (5, 6). Lentiviral 
vectors, like all integrative viral vectors, repre-
sent a risk of insertion mutations, which limits 
their use in clinical applications.
The third-generation Lentiviral Expression 
System is based on vectors developed by Dull 
et al. (7). This system has a significant number 
of safety features, including: 
1. Development of a deletion in the 3′ LTR (∆U3) 
that does not affect the generation of the viral ge-
nome in the producer cell line, but results in self-
inactivation (SIN) of the lentivirus after transduc-
tion of the target cell (8).
2. Reduction of genes to three (i.e. gag, pol, 
and rev).
3. Usage of the VSV-G gene in place of the hu-
man immunodeficiency virus (HIV) envelope 
for production of a high titer lentiviral vector 
with a significantly broadened host cell range 
(9).
4. Insertion of genes encoding the structural and 
packaging components required for making vi-
rus into four separate plasmids (7). 
In this generation of vectors, none of the 
HIV structural genes are actually present in the 
packaged viral genome, thus they are never ex-
pressed in the transduced target cell. So, no new 
replication-competent virus can be produced.
Although the integrated form of lentivirus 
DNA is classically considered to be responsible 
for viral gene expression, several studies have 
suggested that nonintegrated viral DNA can 
support transcription (10, 11). Themis et al. (12) 
have reported the oncogenic potential of lenti-
viral vectors after the transduction of fetal and 
neonatal tissues. These observations have led to 
the development of several integrase-defective 
[Int(-)] lentiviral vectors (13, 14). These vec-
tors were made of specific mutations designed 
to defuse vector integration without affecting 
vector entry into cells, providing short-term 
gene expression. Lentivirus integrase is a 32-
kDa protein with a core domain that contains 
a triad of amino acids essential for its catalytic 
activity, specifically aspartic acid 64, aspartic 
acid 116, and glutamic acid 152 (15-17).
The aim of this study was to design nonin-
tegrating lentiviral vector by mutating aspar-
tic acid 64 to valine (D64V), aspartic acid 116 
to alanine (D116A) and glutamic acid 152 to 
alanine (E152A). We followed the levels of 
expression of the green fluorescent protein 
(GFP) reporter gene from native and noninte-
grating vectors. These vectors can be used for 
transient gene delivery and gene targeting with 
this feature.
Materials and Methods
Construction of lentiviral vector
 In this expereimental assay, lentiviral parti-
cles was produced using pLenti6.2-GW/EmGFP 
Transfer vector (Invitrogen Corporation, Grand 
Island, NY, USA) contained the Emerald GFP 
reporter gene and the human CMV promoter 
with the third-generation ViraPower included 
three helper plasmids, as: pLP1, pLP2, and pLP/
VSVG (Invitrogen Corporation, Grand Island, 
NY, USA). These helper plasmids supply, struc-
tural, and replication proteins required to produce 
functional virus. At first, the Int (-) packaging 
plasmid pLP1 was constructed using three mis-
sense mutations in active sites of the integrase 
catalytic domain. The D64V, D116A and E152G 
changes were made in the amino acid sequence 
with the site directed mutagenesis method by 
primers: D64V Forward 5'-AGCTAGTAT-
GtaCACATTTAGAAGG-3', D64V Reverse 
5'-TTCTAAATGTGTACAtaCTAGCTGC-3', 
D116A Forward 5'-AGTACATACAGcaAATG-
GCAG-3', D116A Reverse 5'-TGCCATTtgCT-
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GTATGTACTG-3', E152G Forward 5'-GTCAA-
GGAGTAATAGctTCTATG-3', E152G Reverse 
5'-CTTTATTCATAGAagCTATTACTC-3'. 
Producing lentivirus in 293T cells
 The new generated Int(-) pLP1 and three oth-
er plasmids, including pLenti6.2-GW/EmGFP, 
pLP2 and pLP/VSV-G were amplified, then 
their concentrations was adjusted to 1 μg/μl. 
293T cells (ATCC No. CRL-11268) reachedare 
grown to 90% confluency in two 100 mm dish-
es. Dishes were transfected with the followings: 
6 μg pLP1 plasmid [Int (-) pLP1 was used in 
order to prepareto make the Integrase-Minus vi-
rus and native pLP1 to make integrating virus], 
14 μg pLenti6.2-GW/EmGFP, 2.4 μg pLP2 and 
3.4 μg pLP/VSV-G with 50 μl Lipofectamine 
2000 (Invitrogen Corporation, Grand Island, 
NY, USA), and 2.5 ml serum-free Dulbecco’s 
modified Eagle’s medium (DMEM) (GIBCO, 
Frankfurt Germany). The cells were then in-
cubated 4-6 hours at 37˚C in a CO
2
 incubator. 
It was followed by adding 3 ml DMEM sup-
plemented with 10% fetal bovine serum (FBS) 
(GIBCO, Frankfurt Germany), 100 IU/ml peni-
cillin, 2 mmol/L L-Glutamine and 100 μg/ml 
Streptomycin (Invitrogen Corporation, Grand 
Island, NY, USA)., Then, the mixture was left 
overnight at 37˚C in a CO
2
 incubator. The su-
pernatants were changed and harvested every 
day for the next 3-4 days. The supernatants were 
centrifuged at 3000 rpm for 15 minutes at +4˚C 
to obtain pellet debris. The viral supernatants 
were transferred through pipet into cryovials in 
1 ml aliquots and stored them at -80˚C.
Titering lentiviral stock
Viral vector titers were assayed using Invitro-
gen’s ViraPower protocol by infection of 293T 
cells at different dilutions (102-106) in a 6-well 
plate (one mock well plus five dilutions) for 
every lentiviral stock (mutant and native). The 
titers were 5~8×106 transducing units (TU)/ml 
and calculated by counting GFP-positive cells 
in two different dilutions with countable num-
ber of cells using a fluorescence microscopy 
(NIKON, Japan).
Transduction of COS7 cells
 The African green monkey cell line, COS-
7 (ATCC No. CRL-1651), was thawed and ex-
panded in DMEM (10% FBS, 100 u/ml penicil-
lin, 100 Ag/ml streptomycin, and 2 mmol/liter 
L-glutamine) to 1×106 cells/ml in culture flasks. 
Cells were then treated with vector at an  mul-
tiplicity of infection (MOI) of 2 in 500 μl for 
2 hours in the presence of 80 mg/ml polybrene 
and expanded to total volume of 2 ml. Cells 
were analyzed for GFP expression by a fluores-
cence microscopy.
The Mazandaran University of Medical Sci-
ences Research Ethics Committee approves this 
study from an ethical point of view.
Results
All integrase-minus vectors gave titers within 
48 hours and they were comparable to those of 
the native vector. It indicated that the mutations 
made to create integrase-minus vectors did not 
affect their ability to produce functional virus 
particles.
 We confirmed that GFP expression from in-
tegrase-minus vectors did not result from inte-
grated provirus because GFP fluorescence lev-
els decreased during the consecutive passages. 
Cells were initially transduced with equal trans-
duction unit (TU) amounts of vector (mutant 
and native), then and cultured and passaged for 
up to 20 days. The cells were consistently ana-
lyzed by a fluorescence microscopy to assure of 
stability assessment of GFP expression through 
passages (Fig 1). The percentage of GFP-posi-
tive cells was stable after transduction with the 
integrative vectors. Also, its growth rates were 
28.42 ± 0.22% and 22.64 ± 1.25% after 3 and 20 
days, respectively. In contrast, the percentage of 
GFP fluorescence cells were rapidly decreased 
in cells transduced with the mutant integrase-
minus vectors, and its growth rates were 31.81 ± 
0.36% and 0.7 ± 0.09% after 3 and 20 days, re-
spectively (Fig 2). Progressive loss of transgene 
expression in dividing cells observed with the 
recombinant vector was consistent with a nonin-
tegrating phenotype.
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Fig 1: GFP expression in dividing cells. The COS7 cells were transduced with equivalent TU amounts of the Int(-) or the native 
vectors. Cells were cultured and analyzed by a fluorescence microscopy at different time interval after transduction to determine 


























Fig 2: GFP expression in COS7 cells in vitro. GFP expression in COS7 cells was evaluated after transduction with equal TU 
amounts of Int(-) or native vectors. The percentage of GFP-expressing cells was evaluated up to 20 days.
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Discussion
In this study, we constructed nonintegrat-
ing lentiviral vectors for high efficiency gene 
transfer to primary cells for transient gene ex-
pression. We produced integrase-defective vec-
tors from HIV-1-based lentiviral vectors by in-
troducing mutations to inactivate the integrase 
catalytic function in the viral genome. Applying 
a packaging plasmid with missense mutations in 
the integrase gene was highly effective to limit 
constant expression. In a standard packaging 
plasmid, the integrase gene open-reading frame 
needs to maintain in order to allow sufficient 
DNA synthesis, so only few missense mutations, 
none of nonsense mutation or large deletion, 
can be used (18). The rare integrations created 
by nonintegrating vectors may also occur with 
other transient gene delivery methods, such as 
adenoviral vectors and nonviral plasmid-medi-
ated gene delivery. The transduction efficiency 
of the D64V vector reported by Yanez-Munoz 
et al. (19) was equal to the integrative vector; 
whereas, the mutant vector described in this 
study showed lower transduction efficiency. Al-
though further comparison studies are needed, 
this difference may be explained by catalyzing 
integration reactions. Integrase enzyme is in-
volved in various steps of the virus life cycle. 
Thus, the integrase gene mutations used in this 
study may impair transduction efficiency. We 
developed an integrase-minus lentiviral vector 
that was nonintegrating and allowed the forma-
tion of circular episomal genomes in the nucleus 
of transduced cells. We showed that this nonin-
tegrated form was efficiently transcribed by the 
cellular machinery. However, transgene expres-
sion with the recombinant vector did not appear 
to be as efficient as its native counterpart. These 
newly developed Int(-) vectors illustrated a step 
forward in the clinical application of lentiviral 
vectors for gene delivery. Since these vectors re-
tain very weak and insignificant in integration 
activity, the risk of insertional mutagenesis is 
totally canceled. Integrase-minus lentiviral vec-
tors can be used for gene targeting if a Target 
gene cassette is placed in the lentivirus gene 
structure. This method decreases disadvantage 
of low efficiency of gene targeting.
Conclusion
These vectors could be used in gene thera-
py methods inquiring transient expression of 
transgene, in dividing cells, and long-term gene 
expression in non-dividing cells.
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